Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis.

Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker A, Hamblett N, Accurso F, Dovey M, Hiatt P, Konstan MW, Moss R, Retsch-Bogart G, Wagener J, Waltz D, Wilmott R, Zeitlin PL, Ramsey B; Cystic Fibrosis Therapeutics Development Network Study Group..

Am J Respir Crit Care Med. 2003 Mar 15;167(6):841-9. Epub 2002 Dec 12.

PMID:
12480612
3.

Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis.

Parkins MD, Elborn JS.

Expert Rev Respir Med. 2011 Oct;5(5):609-22. doi: 10.1586/ers.11.56. Review.

PMID:
21955231
4.

Inhaled antibiotic therapy: What drug? What dose? What regimen? What formulation?

Smith AL.

J Cyst Fibros. 2002 Dec;1(Suppl 2):189-93. Review.

5.

[Use of inhaled tobramycin in patients with cystic fibrosis].

Chermenskiĭ AG, Gembitskaia TE.

Ter Arkh. 2010;82(8):76-8. Review. Russian.

PMID:
20873251
6.

[TOBI Podhaler for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis patients].

Pierart F.

Rev Med Liege. 2013 Sep;68(9):486-8. Review. French.

PMID:
24180205
7.

Inhaled antibiotics for the treatment of chronic bronchopulmonary Pseudomonas aeruginosa infection in cystic fibrosis: systematic review of randomised controlled trials.

Máiz L, Girón RM, Olveira C, Quintana E, Lamas A, Pastor D, Cantón R, Mensa J.

Expert Opin Pharmacother. 2013 Jun;14(9):1135-49. doi: 10.1517/14656566.2013.790366. Epub 2013 Apr 16. Review.

PMID:
23586963
8.
9.

Inhaled liposomal amikacin.

Waters V, Ratjen F.

Expert Rev Respir Med. 2014 Aug;8(4):401-9. doi: 10.1586/17476348.2014.918507. Epub 2014 May 31. Review.

PMID:
24882271
10.

Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients.

Cantón R, Cobos N, de Gracia J, Baquero F, Honorato J, Gartner S, Alvarez A, Salcedo A, Oliver A, García-Quetglas E; Spanish Consensus Group for Antimicrobial Therapy in the Cystic Fibrosis Patient..

Clin Microbiol Infect. 2005 Sep;11(9):690-703. Review.

11.

Pseudomonas acquisition in young patients with cystic fibrosis: pathophysiology, diagnosis, and management.

Rosenfeld M, Ramsey BW, Gibson RL.

Curr Opin Pulm Med. 2003 Nov;9(6):492-7. Review.

PMID:
14534401
12.

Inhaled tobramycin (TOBI).

Bonsignore CL.

Pediatr Nurs. 1998 May-Jun;24(3):258-9. Review.

PMID:
9987427
13.

Efficacy and safety of aerosolized tobramycin in cystic fibrosis.

Pai VB, Nahata MC.

Pediatr Pulmonol. 2001 Oct;32(4):314-27. Review.

PMID:
11568993
14.
15.

[Antibiotic inhalation in cystic fibrosis. A review of the literature].

Steinkamp G.

Monatsschr Kinderheilkd. 1991 Feb;139(2):73-80. Review. German.

PMID:
1903843
16.

Use of inhaled tobramycin in cystic fibrosis.

Shteinberg M, Elborn JS.

Adv Ther. 2015 Jan;32(1):1-9. doi: 10.1007/s12325-015-0179-3. Epub 2015 Jan 27. Review.

PMID:
25620537
17.

Levofloxacin inhalation solution for the treatment of chronic Pseudomonas aeruginosa infection among patients with cystic fibrosis.

Stockmann C, Hillyard B, Ampofo K, Spigarelli MG, Sherwin CM.

Expert Rev Respir Med. 2015 Feb;9(1):13-22. doi: 10.1586/17476348.2015.986469. Epub 2014 Nov 24. Review.

PMID:
25417708
18.

Tobramycin inhalation powder (Tobi Podhaler) for cystic fibrosis.

[No authors listed]

Med Lett Drugs Ther. 2013 Jun 24;55(1419):51-2. Review. No abstract available.

PMID:
23797798
19.

How to use: bacterial cultures in diagnosing lower respiratory tract infections in cystic fibrosis.

Ahmed B, Bush A, Davies JC.

Arch Dis Child Educ Pract Ed. 2014 Oct;99(5):181-7. doi: 10.1136/archdischild-2012-303408. Epub 2013 Dec 12. Review.

PMID:
24334311
20.

Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis.

Geller DE, Pitlick WH, Nardella PA, Tracewell WG, Ramsey BW.

Chest. 2002 Jul;122(1):219-26. Review.

PMID:
12114362

Supplemental Content

Support Center